Granisetron intranasal - Shin Nippon Biomedical Laboratories

Drug Profile

Granisetron intranasal - Shin Nippon Biomedical Laboratories

Alternative Names: Granisetron intranasal - Translational Research; Nasal granisetron (TRG) - Shin Nippon Biomedical Laboratories (SNBL); TRG

Latest Information Update: 23 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Translational Research
  • Developer Shin Nippon Biomedical Laboratories
  • Class Analgesics; Antiemetics; Azabicyclo compounds; Indazoles; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Chemotherapy-induced nausea and vomiting

Highest Development Phases

  • Phase II Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 23 Jun 2015 Granisetron intranasal is still in active development for Chemotherapy-induced nausea and vomiting in USA
  • 15 Oct 2013 Granisetron intranasal - Shin Nippon Biomedical Laboratories is available for licensing as of 15 Oct 2013. http://www.snbl-nds.co.jp
  • 08 Oct 2013 Phase-II development has been completed in USA and Shin Nippon Biomedical Industries is preparing for pivotal phase III trials in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top